Clyde is the only validated CRO for the CiPA Assay
Measures and interprets drug effects on cardiac cell function at clinically relevant doses
Our unique technology is designed to eliminate risk at an earlier stage in development
The only assay to simultaneously measure voltage, calcium, and contractility in the same cells
One assay. Same Cells. Comprehensive & Consistent Data.
The CellOPTIQ assay simultaneously measures voltage, calcium and contractility in the same cells
Clyde will be updating delegates on the recent changes to ICH-S7B/E14 and how hiPSc cardiomyocytes can help fulfil regulatory compliance and also reduce late stage cardiovascular safety failures.
Gossamer Bio, Inc., one of Clyde’s clients, has recently published a series of case studies to highlight the benefits of hiPSC cardiomyocytes for early identification of a broad set of cardiovascular liabilities. These case studies show that hiPSC-CM assay can assess drug-induced negative inotropy as well as electrical conduction alterations.
Clyde Biosciences is the leading in vitro cardiomyocyte safety provider with a track record in developing fully validated safety assays to help solve industry wide challenges regarding cardiovascular liabilities beyond that of hERG. Working with the FDA and large pharmas, Clyde has been instrumental in developing next generation assays for pro arrhythmic risk (CiPA Assay) and negative inotropy (CRACKIT). This publication in the Journal of Cardiovascular Pharmacology highlights our excitation-coupling assay for the parallel assessment of voltage and contractility effects using hiPSC cardiomyocytes.
It has been long established that a hERG assay is not a sufficient predictor for pro-arrythmic actions of a drug (Gintant, 2011; Lu et al., 2008). Since 2013, the FDA has led an initiative designed to validate the use of hiPSC cardiomyocytes in an assay to improve prediction of drug-induced pro-arrhythmic risk (Comprehensive invitro Pro-arrythmia Assay – CiPA). This initiative has stimulated the use if iPSC-cardiomyocytes in industrial work and a growing number of regulatory filings now contain data from iPSC cardiomyocytes.
Clyde Biosciences (Clyde) today announced that the major NC3Rs Crackit Inpulse study demonstrated the accuracy of its CellOPTIQ® technology in predicting the cardiac side-effect risk of drugs. Clyde’s platform provided the majority of data in this large study, a collaboration amongst Clyde’s laboratory, GSK, and Professor Chris Denning at Nottingham University..’ […]
Clyde Biosciences is delighted to announce it has demonstrated superiority over the legacy MEA system in the recent international CiPA study. Initiated by the FDA and by the Health and Environment Sciences Institute, the CiPA study pitted Clyde Biosciences’ CellOPTIQ system against the established micro-electrode array. The results of the study confirmed that Clyde Biosciences’ […]
The Clyde Biosciences team are delighted to have been shortlisted for an award in February’s Scottish Life Sciences Awards. One of three finalists in the Innovative Collaboration award, Clyde has been recognised for its contribution to a global initiative designed to improve the way drugs are assessed for cardiac safety. The initiative, known as CiPA […]
Clyde Biosciences has been recognised in The Scotsman newspaper (December 1, 2017) as a leading innovator in Scottish life sciences. Alongside other Scottish companies, Clyde was noted for its recent project with AstraZeneca examining the effects of certain drug compounds on cardiac cells. Clyde’s unique optical cell function assay service provides information to biotech and […]
Highlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration with Abbvie) AbbVie SPS FINAL Measurements of voltage, intracellular […]
Clyde Biosciences Presents Four Posters at SPS 2017 Highlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration […]
Clyde’s CellOPTIQ® has helped many of the world's best pharma companies solve complex problems more effectively and less expensively than doing so in-house.
Whether you have a current cardiovascular issue or alternatively would like to prevent late stage failures Clyde can help.
Most of our standard studies are completed within 2 weeks.
To enquire about how Clyde could help with your project complete the enquiry form below and we’ll be get back to you as soon as we can. Alternatively email us at info@clydebio.com
